Teva Reports Fourth Quarter and Full Year 2022 Financial Results | Business Wire
Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)